# GLP-1 Drugs and Eating Disorders: Two Questions, One Studied

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-and-eating-disorders

> Five studies covering 182 people make up the whole meta-analytic evidence base in binge eating disorder. What happens when these drugs reach someone with a restrictive eating disorder has never been studied at all.

## Key points

- The entire meta-analytic base in binge eating disorder is 5 studies and 182 people.
- The measured outcome is weight, not binge frequency, which is what defines the condition.
- Trials exclude people with restrictive eating disorders, so the literature is silent on them.
- A BMI threshold is a weight criterion, not an eating disorder screen.

Two questions sit under this heading and only one of them has been studied. The researched question is whether these drugs treat binge eating disorder: a 2025 meta-analysis found five studies covering **182 participants**, with greater weight loss of 3.81 kg.[1] The unstudied question is what happens when a powerful [appetite suppressant](https://glpwatchdog.org/research/fda-approved-appetite-suppressants) reaches someone with a restrictive eating disorder, a group deliberately excluded from every trial. If you are asking the second question about yourself, the evidence below is not the thing you need.

> **If your relationship with eating is the reason you are reading this,** the National Alliance for Eating Disorders runs a free helpline staffed by clinicians: **+1 (866) 662-1235**. Eating disorders carry some of the highest mortality of any psychiatric illness, and they are treatable. That is a better first call than any weight-loss prescriber.

## What has been measured

Of all eating disorders, binge eating disorder is the most common, and it is also the one where a drug affecting appetite and reward signaling has an obvious rationale. A 2025 systematic review and meta-analysis searched four databases and found five eligible studies, together enrolling 182 people.[1] Pooled, GLP-1 treatment produced 3.81 kg more weight loss than comparators.

The headline result is about *weight*, but the condition is defined by episodes of eating and loss of control, not by body size. A treatment can move the scale in someone with binge eating disorder without touching the binges, and weight is the easier thing to measure.

> **Five studies and 182 people is a small literature.** The reviewers say so themselves and call for comprehensive trials, particularly for eating disorders other than binge eating disorder and for long-term effects.[1] Anyone describing these drugs as a treatment for eating disorders is well ahead of that.

## The psychiatric picture is mixed

A 2026 systematic review looked at semaglutide specifically through a psychiatric lens, screening 342 papers down to 37 covering cohorts, pharmacovigilance, open-label studies and randomized trials.[2] Its summary is that semaglutide appears effective and well tolerated across several psychiatric populations, with promise in binge eating disorder, including effects on cognitive symptoms as well as weight.

The same summary notes that these drugs have been linked to depressive symptoms and suicidal ideation, alongside possible antidepressant effects, and describes the evidence for all of it as preliminary.[2] (Bupropion, the antidepressant in Contrave, is contraindicated in bulimia and anorexia; see [antidepressants and a GLP-1](https://glpwatchdog.org/research/antidepressants-and-a-glp1).)

Both findings sit in one review because the field is still immature. Our [suicidality article](https://glpwatchdog.org/research/glp1-suicidal-ideation-what-happened) covers the specific question of self-harm, where the larger evidence base points reassuringly and the labels changed accordingly in February 2026.

## The question nobody is running trials on

Trials of appetite-suppressing drugs exclude people with active restrictive eating disorders, for obvious ethical reasons. That exclusion means the trial literature is silent on a situation that is now common: someone with anorexia nervosa, bulimia, or subclinical restriction obtaining a drug whose entire purpose is to make eating feel unnecessary.

> Trials of these drugs exclude people with active restrictive eating disorders, so the evidence is silent on them.

Two features of the current market make this worse. Telehealth prescribing is fast and largely questionnaire-based, and compounded sellers operate with less screening still (our [pharmacy verification guide](https://glpwatchdog.org/research/how-to-verify-an-online-glp1-pharmacy) covers what a legitimate intake looks like). A BMI threshold is not an eating disorder screen, and someone with a restrictive disorder at a high body weight will pass one.

- **Rapid weight loss can mask a disorder rather than reveal it**, because the loss is attributed to the drug and treated as success.
- **Losing the physical cue of hunger removes a signal** that recovery-oriented treatment works to restore.
- **The drugs are effective**, which means an eating disorder can progress while every number on the chart looks like a good outcome.

## What to do with this

If you have had an eating disorder in the past and are thinking about one of these drugs, that history belongs in the first conversation, not a later one. It is not automatically disqualifying, since binge eating disorder and obesity overlap heavily and the modest evidence points the right way. But it changes who should be involved and what gets monitored.

If someone you know has lost weight rapidly on one of these and their eating has become rigid, secretive or frightening to them, name it out loud. The drug working is not evidence that nothing is wrong.

## Frequently asked questions

### Do GLP-1 drugs treat binge eating disorder?

The evidence is early and small. A 2025 meta-analysis found five studies covering 182 participants, with 3.81 kg more weight loss than comparators. The headline outcome is weight, not binge frequency, and the reviewers call for comprehensive trials before drawing conclusions.

### Are they safe for someone who has had an eating disorder?

That is a clinical judgment, not a general answer, and it belongs in the first conversation rather than a later one. A history is not automatically disqualifying (binge eating disorder and obesity overlap heavily), but it changes who should be monitoring and what they should watch.

### Why are there no trials in anorexia or bulimia?

Trials of appetite-suppressing drugs exclude people with active restrictive eating disorders for ethical reasons. That means the literature is silent on a situation that is now common, and silence is not reassurance.

### Can these drugs make an eating disorder worse?

Nobody has studied it directly, and there are clear mechanisms for concern: rapid weight loss gets attributed to the drug rather than examined, the physical cue of hunger that recovery works to restore is removed, and the illness can progress while every measurement looks like success.

### Does a BMI requirement screen for eating disorders?

No. A BMI threshold is a weight criterion, not a psychiatric screen, and someone with a restrictive disorder at a higher body weight will pass one. Questionnaire-based telehealth intake widens that gap.

## References

1. Radkhah H, Rahimipour Anaraki S, Parhizkar R, et al. The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. Eating and Weight Disorders. 2025. PMID: 39891848. https://pubmed.ncbi.nlm.nih.gov/39891848/
2. Carminati M, Tondello M, Concina A, et al. Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks. International Clinical Psychopharmacology. 2026. PMID: 40577093. https://pubmed.ncbi.nlm.nih.gov/40577093/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1 Drugs and Eating Disorders: Two Questions, One Studied", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/glp1-and-eating-disorders

Canonical HTML page: https://glpwatchdog.org/research/glp1-and-eating-disorders

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
